Antimycobacterial activity of peptide conjugate of pyridopyrimidine derivative against Mycobacterium tuberculosis in a series of in vitro and in vivo models

Kata Horváti, Bernadett Bacsa, Nóra Szabó, Kinga Fodor, Gyula Balka, M. Rusvai, E. Kiss, G. Mező, Vince Grolmusz, B. Vértessy, F. Hudecz, Sz. Bősze

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

New pyridopyrimidine derivatives were defined using a novel HTS in silico docking method (FRIGATE). The target protein was a dUTPase enzyme (EC 3.6.1.23; Rv2697) which plays a key role in nucleotide biosynthesis of Mycobacterium tuberculosis (Mtb). Top hit molecules were assayed in vitro for their antimycobacterial effect on Mtb H37Rv culture. In order to enhance the cellular uptake rate, the TB820 compound was conjugated to a peptid-based carrier and a nanoparticle type delivery system (polylactide-co-glycolide, PLGA) was applied. The conjugate had relevance to in vitro antitubercular activity with low in vitro and in vivo toxicity. In a Mtb H37Rv infected guinea pig model the in vivo efficacy of orally administrated PLGA encapsulated compound was proven: animals maintained a constant weight gain and no external clinical signs of tuberculosis were observed. All tissue homogenates from lung, liver and kidney were found negative for Mtb, and diagnostic autopsy showed that no significant malformations on the tissues occurred.

Original languageEnglish
Pages (from-to)S207-S211
JournalTuberculosis
Volume95
Issue numberS1
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Mycobacterium tuberculosis
Peptides
Computer Simulation
Nanoparticles
Weight Gain
Autopsy
Guinea Pigs
Tuberculosis
Nucleotides
Kidney
Lung
In Vitro Techniques
Liver
Enzymes
Proteins
polylactic acid-polyglycolic acid copolymer

Keywords

  • Guinea pig infection model
  • In silico docking
  • Peptide conjugate
  • PLGA encapsulation
  • Pyridopyrimidines

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Infectious Diseases
  • Microbiology (medical)

Cite this

Antimycobacterial activity of peptide conjugate of pyridopyrimidine derivative against Mycobacterium tuberculosis in a series of in vitro and in vivo models. / Horváti, Kata; Bacsa, Bernadett; Szabó, Nóra; Fodor, Kinga; Balka, Gyula; Rusvai, M.; Kiss, E.; Mező, G.; Grolmusz, Vince; Vértessy, B.; Hudecz, F.; Bősze, Sz.

In: Tuberculosis, Vol. 95, No. S1, 01.06.2015, p. S207-S211.

Research output: Contribution to journalArticle

@article{b745bcc7c005453eb34829be9b67b34a,
title = "Antimycobacterial activity of peptide conjugate of pyridopyrimidine derivative against Mycobacterium tuberculosis in a series of in vitro and in vivo models",
abstract = "New pyridopyrimidine derivatives were defined using a novel HTS in silico docking method (FRIGATE). The target protein was a dUTPase enzyme (EC 3.6.1.23; Rv2697) which plays a key role in nucleotide biosynthesis of Mycobacterium tuberculosis (Mtb). Top hit molecules were assayed in vitro for their antimycobacterial effect on Mtb H37Rv culture. In order to enhance the cellular uptake rate, the TB820 compound was conjugated to a peptid-based carrier and a nanoparticle type delivery system (polylactide-co-glycolide, PLGA) was applied. The conjugate had relevance to in vitro antitubercular activity with low in vitro and in vivo toxicity. In a Mtb H37Rv infected guinea pig model the in vivo efficacy of orally administrated PLGA encapsulated compound was proven: animals maintained a constant weight gain and no external clinical signs of tuberculosis were observed. All tissue homogenates from lung, liver and kidney were found negative for Mtb, and diagnostic autopsy showed that no significant malformations on the tissues occurred.",
keywords = "Guinea pig infection model, In silico docking, Peptide conjugate, PLGA encapsulation, Pyridopyrimidines",
author = "Kata Horv{\'a}ti and Bernadett Bacsa and N{\'o}ra Szab{\'o} and Kinga Fodor and Gyula Balka and M. Rusvai and E. Kiss and G. Mező and Vince Grolmusz and B. V{\'e}rtessy and F. Hudecz and Sz. Bősze",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.tube.2015.02.026",
language = "English",
volume = "95",
pages = "S207--S211",
journal = "Tuberculosis",
issn = "1472-9792",
publisher = "Churchill Livingstone",
number = "S1",

}

TY - JOUR

T1 - Antimycobacterial activity of peptide conjugate of pyridopyrimidine derivative against Mycobacterium tuberculosis in a series of in vitro and in vivo models

AU - Horváti, Kata

AU - Bacsa, Bernadett

AU - Szabó, Nóra

AU - Fodor, Kinga

AU - Balka, Gyula

AU - Rusvai, M.

AU - Kiss, E.

AU - Mező, G.

AU - Grolmusz, Vince

AU - Vértessy, B.

AU - Hudecz, F.

AU - Bősze, Sz.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - New pyridopyrimidine derivatives were defined using a novel HTS in silico docking method (FRIGATE). The target protein was a dUTPase enzyme (EC 3.6.1.23; Rv2697) which plays a key role in nucleotide biosynthesis of Mycobacterium tuberculosis (Mtb). Top hit molecules were assayed in vitro for their antimycobacterial effect on Mtb H37Rv culture. In order to enhance the cellular uptake rate, the TB820 compound was conjugated to a peptid-based carrier and a nanoparticle type delivery system (polylactide-co-glycolide, PLGA) was applied. The conjugate had relevance to in vitro antitubercular activity with low in vitro and in vivo toxicity. In a Mtb H37Rv infected guinea pig model the in vivo efficacy of orally administrated PLGA encapsulated compound was proven: animals maintained a constant weight gain and no external clinical signs of tuberculosis were observed. All tissue homogenates from lung, liver and kidney were found negative for Mtb, and diagnostic autopsy showed that no significant malformations on the tissues occurred.

AB - New pyridopyrimidine derivatives were defined using a novel HTS in silico docking method (FRIGATE). The target protein was a dUTPase enzyme (EC 3.6.1.23; Rv2697) which plays a key role in nucleotide biosynthesis of Mycobacterium tuberculosis (Mtb). Top hit molecules were assayed in vitro for their antimycobacterial effect on Mtb H37Rv culture. In order to enhance the cellular uptake rate, the TB820 compound was conjugated to a peptid-based carrier and a nanoparticle type delivery system (polylactide-co-glycolide, PLGA) was applied. The conjugate had relevance to in vitro antitubercular activity with low in vitro and in vivo toxicity. In a Mtb H37Rv infected guinea pig model the in vivo efficacy of orally administrated PLGA encapsulated compound was proven: animals maintained a constant weight gain and no external clinical signs of tuberculosis were observed. All tissue homogenates from lung, liver and kidney were found negative for Mtb, and diagnostic autopsy showed that no significant malformations on the tissues occurred.

KW - Guinea pig infection model

KW - In silico docking

KW - Peptide conjugate

KW - PLGA encapsulation

KW - Pyridopyrimidines

UR - http://www.scopus.com/inward/record.url?scp=84931567017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931567017&partnerID=8YFLogxK

U2 - 10.1016/j.tube.2015.02.026

DO - 10.1016/j.tube.2015.02.026

M3 - Article

C2 - 25728610

AN - SCOPUS:84931567017

VL - 95

SP - S207-S211

JO - Tuberculosis

JF - Tuberculosis

SN - 1472-9792

IS - S1

ER -